New study confirms the existence of 'trial effect' in HIV clinical trials

July 13, 2011 in HIV & AIDS

A new study by investigators from the University of North Carolina at Chapel Hill School of Medicine has confirmed the existence of a "trial effect" in clinical trials for treatment of HIV.

Trial effect is an umbrella term for the benefit experienced by simply by virtue of their participating in the trial. It includes the benefit of newer and more effective treatments, the way those treatments are delivered, increased care and follow-up, and the patient's own as a result of being under observation.

"Trial effect is notoriously difficult to test," said Prema Menezes, PhD, assistant professor of medicine at UNC and lead author of the study. "Our study used the objective finding of to test our hypothesis," she said.

Researchers compared among patients who began highly (HAART) in a clinical trial with patients who received HAART in routine clinical care in two different time periods, 1996-1999 and 2000-2006. They found clear evidence of a trial effect during the earlier period, but not during the later period. Researchers offer that improvements to antiretroviral therapy (fewer pills and fewer side effects), and the change in attitude to HIV, which has come to be seen by many as a chronic, but treatable infection, may be among the explanations for the lack of demonstrable trial effect in the later period.

"This is the first study to clearly demonstrate a trial effect in HIV , and this has important implications moving forward," Menezes said. Documentation of a clinical trial effect should be considered when interpreting the generalizability of clinical trial results. At the same time, the fact that no trial effect was observed in the current HAART period argues that the efficacy demonstrated in clinical trials is likely to predict the effectiveness of the therapy in broader treatment populations. Clinicians and public health officials may have increased confidence that treatment guidelines based on clinical trial data are relevant to routine clinical care.

More information: Menezes P, Miller WC, Wohl DA, Adimora AA, Leone PA, et al. (2011) Does HAART Efficacy Translate to Effectiveness? Evidence for a Trial Effect. PLoS ONE 6(7): e21824. doi:10.1371/journal.pone.0021824

Provided by Public Library of Science search and more info website

3 /5 (1 vote)  

Rank 3 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Mortality rates decrease, chronic disease rates increase among HIV+ ICU patients

The expanded use of antiretrovirals, potent drugs used to treat retroviral infections such as human immunodeficiency virus (HIV), has been linked to significant decreases in hospital mortality rates among severely ill HIV-positive(HIV+) ...

HIV & AIDS created May 23, 2012 | popularity not rated yet | comments 0

Newly discovered breast milk antibodies help neutralize HIV

Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, ...

HIV & AIDS created May 22, 2012 | popularity 5 / 5 (3) | comments 1 | with audio podcast

Reactions to HIV drug have autoimmune cause, reports AIDS journal

Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according ...

HIV & AIDS created May 22, 2012 | popularity 5 / 5 (1) | comments 0

Is the U.S. ready for home HIV tests?

At the pharmacy, you can buy anything from tea kettles to Tylenol. But what if you could buy a rapid HIV test over the counter and test yourself in the privacy of your own home?

HIV & AIDS created May 21, 2012 | popularity not rated yet | comments 0 | with audio podcast

Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use

A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In lab ...

HIV & AIDS created May 17, 2012 | popularity 5 / 5 (1) | comments 0


Most occupational injury and illness costs are paid by the government and private payers

UC Davis researchers have found that workers' compensation insurance is not used nearly as much as it should be to cover the nation's multi-billion dollar price tag for workplace illnesses and injuries. Instead, almost 80 ...

Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Inherited DNA change explains overactive leukemia gene

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare

A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.